The management plan for a patient with Crohn's disease should take into account the
activity, site and behaviour of disease, and should always be discussed with the patient …

The development of therapeutic antibodies has evolved over the past decade into a
mainstay of therapeutic options for patients with autoimmune and inflammatory diseases …

Fistulating Crohn's disease (CD) comprises fistulae arising in the perianal area, together
with those communicating between the intestine and other organs or the abdominal wall …

OBJECTIVES: Studies evaluating the correlation between the widely used Simple
Endoscopic Score for Crohn's disease (SES-CD) and noninvasive markers are scarce. The …

OBJECTIVES: Human anti-chimeric antibodies (HACAs) and subtherapeutic infliximab
concentrations are associated with decreased duration of response. We evaluated the …

BACKGROUND & AIMS: Clinical trials of Crohn's disease generally use the Crohn's Disease
Activity Index to assess disease activity; these calculations are complex, time-consuming …

Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have
become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid …

The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory
bowel diseases (IBDs). The overall objective was to better understand and explore primary …

Results from clinical trials of biologic anti-TNF drugs performed in the late 1990s confirmed
the biological relevance of TNF function in the pathogenesis of chronic noninfectious …

We evaluated the safety and clinical outcome of autologous nonmyeloablative
hematopoietic stem cell transplantation (HSCT) in patients with severe Crohn disease (CD) …